Figure 2.

Luteolin promotes CD55-TRAIL replication and associated gene expression. (A) Colorectal cancer HT-29 cells were treated with CD55-Trail (15 MOI; a and b), or with CD55-Trail (15 MOI) plus luteolin (25 µM; c and d). Images a and c were captured using a light microscope (0.2 mm fields; magnification, ×200); b and d were captured using a fluorescence microscope (0.2 mm fields; magnification, ×200). (B) E1A and TRAIL expression was detected by western blot analysis. (C) Cell viability was detected via an MTT assay. The quantitated data were processed using CalcuSyn software, and the CI values of the treatment groups are represented by X-marks. All data are presented as the mean ± standard deviation. n=3. *P<0.05, **P<0.01. CD55, complement decay-accelerating factor; TRAIL, tumor necrosis factor ligand superfamily member 10; MOI, multiplicity of infection; CI, combination index; E1A, early region 1A; EGFP, enhanced green fluorescent protein.